IBEX Snapshot
IBEX Technologies knows what's what when it comes to proteins. IBEX develops and sells a series of proprietary enzymes for use in pharmaceutical research, particularly for arthritis and oncology. It markets diagnostic assays for use in arthritis tests that monitor the deterioration of cartilage; other assays monitor the rebuilding of cartilage. IBEX provides enzymes for use as reagents used in hemostasis monitoring devices (for blood coagulation detection during certain surgical procedures). The majority of the company's sales are in the US (50%), followed by Europe and Canada, where revenues are split evenly. Lloyd Miller III, general partner of Milfam II investment trust, holds about 11% of the company's shares.
